Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
NicOx SA
NicOx SA
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Nicox appoints Gavin Spencer as CEO
Spencer’s initial focus will be on securing financing to complete the Phase III trial of NCX 470, Denali
Recruitment
Nicox appoints Dr Tomas Navratil Head of Development
Research & Development
Lauren P. Silvernail appointed to Nicox Board of Directors
Renewal of the terms of office of Birgit Stattin Norinder and Michele Garufi
Finance
Nicox to transfer commercial operations to new company led by GHO Capital
The deal values Nicox's operations at up to €26m
Regulatory
US FDA grants priority review for Nicox's AC-170 new drug application
FDA assigns Prescription Drug User Fee Act (PDUFA) goal date of 18 October 2016
Finance
Nicox to buy Aciex Therapeutics
Part of strategy to create an international ophthalmic company built around therapeutics and diagnostics
Pharmaceutical
NicOx appoints three commercial executives in the US
In preparation for the launch of ophthalmic product AdenoPlus
Subscribe now